Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
DAB2
REST API REST API
Homo sapiens
DAB2 is differentially expressed in 384 experiments: 170 organism parts: kidney, placenta, ... (168 more);, 282 disease states: normal, prostate carcinoma, ... (280 more);, 150 cell types 552 cell lines 55 compound treatments and 80 other conditions.
Synonyms DOC-2
Orthologs DAB2_RAT (Rattus norvegicus)   DAB2 (Gallus gallus)   dab2 (Danio rerio)   ENSCING00000012307 (Ciona intestinalis)   Dab2 (Mus musculus)   DAB2 (Bos taurus)   Dab (Drosophila melanogaster)   dab2 (Xenopus laevis)   DAB2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, negative regulation of cell growth, cell morphogenesis involved in differentiation, negative regulation of transcription, DNA-dependent, protein binding, cytoplasm, positive regulation of proteasomal ubiquitin-dependent protein catabolic process, cell proliferation, membrane, receptor-mediated endocytosis, clathrin coated vesicle membrane, coated pit, nucleus, cytoplasmic vesicle, apical plasma membrane, protein C-terminus binding, positive regulation of transcription, DNA-dependent, negative regulation of protein binding, in utero embryonic development, pinocytosis, excretion, negative regulation of canonical Wnt receptor signaling pathway, positive regulation of protein phosphorylation, positive regulation of Wnt receptor signaling pathway, planar cell polarity pathway
InterPro Term PTyr_interaction_dom
UniProt Accession P98082, D6REB1, D6RIA5, D6RGZ1, D6RFF7
Search EB-eye ENSG00000153071
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, E-GEOD-3526, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (54 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639, E-GEOD-3529
AGS
2
E-GEOD-15460, E-MTAB-37
BT-474
2
E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
HT1080
2
E-MTAB-37, E-GEOD-20089
546 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (65 experiments)

Factor Value U/D Experiments
stromal cell
1
4
E-MEXP-2034, E-GEOD-1460, E-MEXP-1327, E-GEOD-3998, E-GEOD-10797 ... (5 experiments)
human embryonic stem cell
3
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
mononuclear cell
3
E-GEOD-6053, E-GEOD-7307, E-MEXP-66
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
CD8+ T cell
1
2
E-MTAB-25, E-AFMX-5, E-GEOD-19069
144 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (83 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-MTAB-62, E-GEOD-3868, E-GEOD-96, E-MEXP-2034
acute promyelocytic leukemia
3
E-GEOD-96, E-GEOD-995, E-MTAB-62
glioblastoma
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-37
lung adenocarcinoma
3
E-MTAB-62, E-MEXP-231, E-GEOD-2514
leiomyosarcoma
2
E-MEXP-1922, E-MTAB-62
lymphoma
2
E-MTAB-37, E-MTAB-62
276 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-GEOD-4748, ... (38 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-4748
ethanol
2
E-MEXP-2241, E-GEOD-3113
FCCP
1
E-MEXP-2285
placebo
1
E-MEXP-1335
nocodazole
1
E-GEOD-5258
water
1
E-MEXP-1372
49 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86 years
1
1
E-GEOD-4922
86
1
1
E-GEOD-3494


Age at onset
studied in E-GEOD-21521

Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-2509, ... (11 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (8 experiments)

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, ... (17 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, E-GEOD-2487, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-3860, E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Processing time: 0.445 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM